Literature DB >> 6359379

Effect of pneumococcal vaccination on upper respiratory tract infections in children. Design of a follow-up study.

C Rosén, P Christensen, B Hovelius, K Prellner.   

Abstract

Children, aged 6 months to 5 years, were pair-matched with respect to age and history of otitis media acuta. The 405 children received either a subcutaneous injection of Pneumovax (a 14-valent pneumococcal vaccine) or of saline, in a double-blind fashion. The follow-up period for each child was 1 1/2 years. In children younger than 2 years at vaccination no difference was recorded between vaccinees and controls concerning the number of consultations due to otitis media acuta or to other upper respiratory tract infections. In children older than 2 years at vaccination a reduction in the overall frequency of visits due to upper respiratory tract infections was observed after vaccination. The incidence of otitis media acuta was reduced during the first postvaccinal year while visits due to tonsillitis and pharyngitis were reduced during the whole follow-up period in vaccinees as compared to controls.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6359379

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  6 in total

1.  Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates.

Authors:  C Peeters; A M Tenbergen-Meekes; J Poolmann; B Zegers; G Rijkers
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Authors:  F M Russell; J R Carapetis; A Balloch; P V Licciardi; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; J Nelson; G B Byrnes; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

Review 3.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

Authors:  F M Russell; P V Licciardi; A Balloch; V Biaukula; L Tikoduadua; J R Carapetis; J Nelson; A W J Jenney; L Waqatakirewa; S Colquhoun; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

Review 5.  Vaccines for preventing pneumococcal infection in adults.

Authors:  Sarah Moberley; John Holden; David Paul Tatham; Ross M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

6.  Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.

Authors:  A E Fiore; O S Levine; J A Elliott; R R Facklam; J C Butler
Journal:  Emerg Infect Dis       Date:  1999 Nov-Dec       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.